Sugi Predict

Sugi Predict / Compounds / SCHEMBL2108299

SCHEMBL2108299

SCHEMBL2108299

CC(C)(O)CCCCCc1cccc(C=Cc2ccc(C(O)O)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HMGCR P04035 1/20 0.53
▸ HDAC4 P56524 1/20 0.39
▸ MEF2D Q14814 1/20 0.39
▸ VDR P11473 7/20 0.38
▸ CYP24A1 Q07973 2/20 0.38
▸ LMNA P02545 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ LPL P06858 1/20 0.35
▸ LIPG Q9Y5X9 1/20 0.35
▸ PPARG P37231 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ PLAU P00749 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6155341 0.99 HMGCR (0.54) HMGCRHDAC4MEF2DVDRCYP24A1
SCHEMBL6154939 0.91 HMGCR (0.54) HMGCRHDAC4MEF2DVDRCYP24A1
SCHEMBL2106866 0.90 HMGCR (0.55) HMGCRHDAC4MEF2DVDRCYP24A1
SCHEMBL2107468 0.87 SPHK1 (0.40) HMGCRVDRCYP24A1LMNAPKM
SCHEMBL6155540 0.86 SPHK1 (0.41) HMGCRVDRCYP24A1LMNAPKM
SCHEMBL2107968 0.85 HMGCR (0.55) HMGCRHDAC4MEF2DVDRCYP24A1
SCHEMBL2107967 0.85 HMGCR (0.55) HMGCRHDAC4MEF2DVDRCYP24A1
SCHEMBL2107474 0.82 HMGCR (0.55) HMGCRHDAC4VDRLMNAPKM
SCHEMBL2107473 0.82 HMGCR (0.55) HMGCRHDAC4VDRLMNAPKM
SCHEMBL2108149 0.82 HMGCR (0.57) HMGCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 — — EP claimed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 — — US claimed
US-11730682-B2 Self-standing cosmetic sheet L'OREAL (FR) 2023-08-22 — — US disclosed
US-20180235849-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2018-08-23 — — US disclosed
US-9949897-B2 Self-standing cosmetic sheet L'OREAL (FR) 2018-04-24 — — US disclosed
US-20150209243-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2015-07-30 — — US disclosed
EP-2836187-A1 SELF-STANDING COSMETIC SHEET L'Oréal (FR) 2015-02-18 — — EP disclosed
EP-1658838-B1 Emulsification system for use in cosmetics ORÉAL L (FR) 2014-07-02 — — EP disclosed
WO-2013153678-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2013-10-17 — — WO disclosed
US-8158136-B2 Emulsification system for use in cosmetics L'ORÉAL (FR) 2012-04-17 — — US disclosed
US-20070025937-A1 Cosmetic compositions containing hydroquinone L'OREAL S.A. (FR) 2007-02-01 — — US disclosed
US-20060039936-A1 Emulsification system for use in cosmetics L'OREAL (FR) 2006-02-23 — — US disclosed
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof L'OREAL (FR) 2005-08-04 — — US disclosed
EP-1559398-A1 Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins L'OREAL (FR) 2005-08-03 — — EP disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 — — EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 — — US disclosed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 — — US disclosed
EP-1262168-A1 Composition containing fibres to combat the skin aging process L'OREAL (FR) 2002-12-04 — — EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 — — EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 HMGCR 283/4885HDAC4 281/4885MEF2D 1750/4885
US-20150209243-A1 SELF-STANDING COSMETIC SHEET CUTA, SUCLG1, SIGLEC7 HMGCR 691/4885HDAC4 1108/4885MEF2D 2507/4885
US-20180235849-A1 SELF-STANDING COSMETIC SHEET CUTA, DSG1, SUCLG1 HMGCR 565/4885HDAC4 2737/4885MEF2D 1511/4885
US-11730682-B2 Self-standing cosmetic sheet CUTA, DSG1, SUCLG1 HMGCR 565/4885HDAC4 2737/4885MEF2D 1511/4885
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof KRT18, PROC, CUTA HMGCR 1113/4885HDAC4 3489/4885MEF2D 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.